Class / Patent application number | Description | Number of patent applications / Date published |
514254100 | Ring oxygen in the additional hetero ring | 81 |
20080214564 | MACROLIDE COMPOUND IN SOLID FORM, PROCESS FOR PREPARATION THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME - The present invention provides the compound of formula (I) in a solid form which, as a bulk medicament for pharmaceutical manufacture, is uniform, has a high purity, and is easy to work with. The invention further provides a process for preparing this compound, and pharmaceutical compositions containing the same. A solid form of (8E,12E,14E)-7-{(4-cycloheptylpiperazin-1-yl)carbonyl}oxy-3,6,16,21-tetrahydroxy-6,10,12,16,20-pentamethyl-18,19-epoxytricosa-8,12,14-trien-11-olide which has uniform specifications and is easy to work with was developed. | 09-04-2008 |
20080255146 | NOVEL PHYSIOLOGICALLY ACTIVE SUBSTANCES - The present invention relates to a compound represented by the formula (I): | 10-16-2008 |
20080269245 | Dioxanes and uses thereof - In recognition of the need to develop novel therapeutic agents and efficient methods for the synthesis thereof, the present invention provides novel compounds of general formula (I): | 10-30-2008 |
20080275059 | NOVEL PHYSIOLOGICALLY ACTIVE SUBSTANCES - The present invention relates to a compound represented by the formula (I): | 11-06-2008 |
20090156611 | MAMMALIAN HEDGEHOG SIGNALING MODULATORS - The disclosure relates to compositions for and methods of inhibiting the mammalian Hedgehog signaling pathway. | 06-18-2009 |
20090170869 | PIPERAZINE DERIVATIVE HAVING AFFINITY FOR THE HISTAMINE H3 RECEPTOR - The present invention relates to 1-(1-methylethyl)-4-{[4-(tetrahydro-2H-pyran-4-yloxy)phenyl]carbonyl}piperazine | 07-02-2009 |
20090325978 | STABLE LYOPHILIZED PREPARATION - The present invention provides a lyophilized preparation that has excellent stability over time and excellent solubility when reconstituted, and that contains (8E,12E,14E)-7-((4-cycloheptylpiperazin-1-yl)carbonyl)oxy-3,6,16,21-tetrahydroxy-6,10,12,16,20-pentamethyl-18,19-epoxytricosa-8,12,14-trien-11-olide. The present invention discloses a lyophilized preparation containing 1) (8E,12E,14E)-7-((4-cycloheptylpiperazin-1-yl)carbonyl)oxy-3,6,16,21-tetrahydroxy-6,10,12,16,20-pentamethyl-18,19-epoxytricosa-8,12,14-trien-11-olide or a pharmaceutically acceptable salt thereof, 2) a pH regulator for adjusting a pH of the preparation to between 5 and 8, and 3) at least one of excipients selected from the groups consisting of sugars and sugar alcohols. | 12-31-2009 |
20100120789 | Compound - There is provided a compound having Formula I | 05-13-2010 |
20100179168 | ARYL AND HETEROARYL SULPHONAMIDES AS GROWTH HORMONE SECRETAGOGUE RECEPTOR AGONISTS - The present invention therefore provides compounds of formula (I) or pharmaceutically acceptable salts thereof: (I) processes for their preparation, pharmaceutical compositions containing the same and to their use in the treatment of gastrointestinal and other disorders. | 07-15-2010 |
20100204242 | Piperazine Derivative Having Affinity for the Histamine H3 Receptor - The present invention relates to 1-(1-methylethyl)-4-{[4-(tetrahydro-2H-pyran-4-yloxy)phenyl]carbonyl}piperazine | 08-12-2010 |
20110105522 | KETOCONAZOLE-DERIVATIVE ANTAGONIST OF HUMAN PREGNANE X RECEPTOR AND USES THEREOF - The application discloses ketoconazole derivatives that are antagonists of the human pregnane X receptor (PXR), methods of preparing the derivatives, uses of the derivatives with drug therapy, and methods of inhibiting tumor cell proliferation and multidrug resistance using inhibitors of PXR. | 05-05-2011 |
20110178098 | ANTICANCER COMPOUNDS AND METHODS OF MAKING AND USING SAME - In one aspect, the invention relates to compounds having anticancer activity; synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating disorders associated with uncontrolled cellular proliferation using the compounds and compositions. This abstract is intended to be used as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention. | 07-21-2011 |
20120225889 | USE OF MACROCYCLIC LACTONE DERIVATIVES FOR THE TREATMENT OF INFLAMMATORY DISORDERS - The present invention provides use of the compounds represented by formula (1): wherein, R | 09-06-2012 |
20120245183 | MACROCYCLIC LACTONE DERIVATIVES FOR THE TREATMENT OF CANCER - The present invention provides compounds represented by formula (1): wherein, R | 09-27-2012 |
20130158046 | BIOCOMPATIBLE BIODEGRADABLE FUMAGILLIN ANALOG CONJUGATES - Fumagillin analog polymer conjugates, methods of making fumagillin analog polymer conjugates, compositions comprising a polymer conjugate of a fumagillin analog, and methods for treating cancer, or treating angiogenic diseases comprising administering to a subject in need thereof an effective amount of a polymer conjugate of a fumagillin analog, are described. Also described are novel fumagillin analogs, methods of making fumagillin analogs, compositions comprising at least one fumagillin analog, and methods for treating cancer, or treating angiogenic diseases comprising administering to a subject in need thereof an effective amount of a fumagillin analog. | 06-20-2013 |
20140275112 | Compounds For Stabilizing Ryanodine Receptors From Aberrant Levels Of Calcium Release - Disclosed herein are methods and compositions comprising compounds capable of normalizing neuronal calcium dyshomeostasis. Also disclosed are methods comprising these compounds for treating neuronal or neurological disorders, including Alzheimer's disease, Parkinson's disease, Huntington's disease, fronto-temporal dementia, Pick's disease, chronic traumatic encepholopathy, traumatic brain injury, stroke, cerebellar ataxia, multiple sclerosis, Down syndrome, and aging-related CNS disorders. | 09-18-2014 |
20140296254 | NOVEL DISUBSTITUTED 3,4-DIAMINO-3-CYCLOBUTENE-1,2-DIONE COMPOUNDS FOR USE IN THE TREATMENT OF CHEMOKINE-MEDIATED DISEASES - Disubstituted 3,4-diamino-3-cyclobutene-1,2-dione compounds are described that correspond to general formula (I). Also described, are pharmaceutical compositions that include these compounds and methods of using these compounds and compositions for the treatment of chemokine-mediated diseases. | 10-02-2014 |
20140364439 | MARKERS ASSOCIATED WITH CHRONIC LYMPHOCYTIC LEUKEMIA PROGNOSIS AND PROGRESSION - The present invention provides methods and devices related to markers (or biomarkers) associated with chronic lymphocytic leukemia (CLL). Examples of these markers include drivers of CLL progression. The invention contemplates, inter alia, detecting the clonal, including subclonal, profile of CLL in a subject and the presence (or absence) of subclonal driver mutations, and utilizing this information in predicting disease progression, need, timing and/or nature of treatment regimen, and likelihood and frequency of relapse. | 12-11-2014 |
20150051220 | COMPOUNDS FOR USE IN THERAPY - A compound of formula (I) | 02-19-2015 |
20160024038 | Compounds For Stabilizing Ryanodine Receptors From Aberrant Levels Of Calcium Release - Disclosed herein are methods and compositions comprising compounds capable of normalizing neuronal calcium dyshomeostasis. Also disclosed are methods comprising these compounds for treating neuronal or neurological disorders, including Alzheimer's disease, Parkinson's disease, Huntington's disease, fronto-temporal dementia, Pick's disease, chronic traumatic encepholopathy, traumatic brain injury, stroke, cerebellar ataxia, multiple sclerosis, Down syndrome, and aging-related CNS disorders. | 01-28-2016 |
20180022722 | Compounds for Stabilizing Ryanodine Receptors from Aberrant Levels of Calcium Release | 01-25-2018 |
20220133715 | METHODS OF TREATING VENETOCLAX-RESISTANT ACUTE MYELOID LEUKEMIA - The present invention concerns novel methods of treatment for venetoclax-resistant acute myeloid leukemia, particularly in subjects with a low expression of TP53 protein or expression of TP53 protein associated with a mutation of the TP53 gene, the methods comprising administering to the subject in need thereof a therapeutically effective amount of a NTRK/ALK/ROS1 inhibitor, or a pharmaceutically acceptable salt thereof. | 05-05-2022 |
514254110 | Polycyclo ring system having the additional oxygen hetero ring as one of the cyclos | 59 |
20090076030 | Piperazine compounds - A compound selected from those of formula (I): | 03-19-2009 |
20090118302 | Novel Benzopyran Derivatives Having Inhibitory Activities Against Liver Fibrosis and Cirrhosis and Their Pharmaceutical Uses - The present invention relates to a novel benzopyran derivative having goodantagonistic activity on TGF-β receptor which can be effectively used as a prophylactic and therapeutic agent for liver disease as well as several fibroplasiadiseases such as hepatic fibrosis, liver cirrhosis, pulmonary fibrosis, dermatosclerosis, glomerular fibrosis and the like; and a pharmaceutical use thereof. | 05-07-2009 |
20090131452 | BENZENESULFONANILIDE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5-HT6 RECEPTOR - The present invention relates to novel benzenesulfonanilide compounds of the formulae I and I′ and physiologically tolerated acid addition salts and the N-oxides thereof. The compounds possess valuable therapeutic properties and are particularly suitable, for treating diseases that respond to modulation of the serotonin 5-HT | 05-21-2009 |
20090170870 | AMIDINE-CONTAINING COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS - The invention relates to compounds of formula I: | 07-02-2009 |
20090176801 | NOVEL LAPACHONE COMPOUNDS AND METHODS OF USE THEREOF - The invention provides lapachone analogs and derivatives as well as methods of use thereof. These compounds can be used in pharmaceutical compositions for the treatment or prevention of cell proliferation disorders. These compounds can also be used in the treatment or prevention of cancer or precancerous conditions. | 07-09-2009 |
20090181980 | Synergistic Pharmaceutical Composition - A therapeutic agent for administration to a bacterium or to the environment thereof which agent comprises synergistically effective amounts of (i) an RNA polymerase inhibitor and (ii) an ALS enzyme inhibitor. | 07-16-2009 |
20090298850 | Treatment for Neurological and Mental Disorders - Methods for treating neurological or mental disorders in humans and the symptoms associated therewith are provided by administering eltoprazine and/or related compounds. In some embodiments, specific symptoms are treated by administering eltoprazine and/or a related compound in an effective amount to ameliorate the symptoms. Of particular significance are symptoms that are associated with cognitive dysfunction where eltoprazine will improve the symptoms and the disorder associated with that symptom. Of particular interest are non-ADHD-associated inattention, hyperactivity and impulsiveness. The methods provided herein are especially useful for improving functional recovery after CNS injury such as stroke where improved cognitive function will facilitate the acquisition of learning and memory of rehabilitative tasks. | 12-03-2009 |
20100016333 | Once-a-day (RNA-Polymerase Inhibiting or phenazine) - dihydropteroate synthase inhibiting - dihydrofolate reductase inhibiting antibiotic pharmaceutical product, formulation thereof, and use thereof in treating infection caused by Methicillin-Resistant Staphylococcus aureus - Disclosed are once-a-day antibiotic products for treating Methicillin-Resistant | 01-21-2010 |
20100029683 | Methods for regulating cell mitosis by inhibiting serine/threonine phosphateses - Disclosed herein are methods of inhibiting proliferation of a cancer cell or inducing apoptosis of a cancer cell, which does not overexpress N—CoR. Also disclosed herein are methods of inhibiting proliferation or inducing apoptosis of a cancer cell that overexpresses TCTP and methods for determining whether a compound is effective in inducing cell death. | 02-04-2010 |
20100113477 | Inhibitors of mycobacterium tuberculosis malate synthase, methods of making and uses thereof - The present invention provides aryl- or heteroaryl-diketo acid compounds effective to inhibit an activity of a Mycobacterial malate synthase enzyme or to inhibit a malate synthase activity in other bacteria having the enzyme. The compounds may be phenyl-naphthyl-, or thienyl-substituted diketo acids and carboxylate derivatives thereof. Also provided are methods of treating tuberculosis or other pathophysiological conditions associated with a malate synthase enzyme with the inhibitory compounds and methods of in silico design of the inhibitory compounds. In addition, the present invention provides the inhibitory compounds designed by this method. Furthermore, three-dimensional X-ray crystal structures of the Mycobacterial malate synthase complexed with the inhibitory compounds are provided. Further still a method for stabilizing an aromatic or heteroaromatic diketo acid or its prodrug or close analog in solution by derivatizing at least the ortho position on the aromatic ring is provided. | 05-06-2010 |
20100137334 | Piperidine and Piperazine Derivatives - Compounds of general formula (Ia): in which R | 06-03-2010 |
20100168129 | DRUGS WITH ANTICHOLESTATIC ACTIVITY - New compounds belonging to the structural formula (I) are described. | 07-01-2010 |
20100179170 | HETEROGENEOUSLY CONFIGURED MULTIPARTICULATE GASTROINTESTINAL DRUG DELIVERY SYSTEM - This invention relates to a heterogeneously configured multiparticulate drug delivery system for gastrointestinal delivery of at least one or a combination of active pharmaceutical compositions. The system comprises a multiplicity of enterosoluble or gastrosoluble multiparticulates loaded with the active pharmaceutical composition or compositions for the site-specific delivery of said active pharmaceutical composition or compositions to a specific region in the gastrointestinal tract of a human or animal body. The system can be supplied as reconstitutable granules which are reconstituted immediately before oral administration. | 07-15-2010 |
20100179171 | Pharmacological Treatment of Parkinson's Disease - The present invention relates to the co-administration of two neurotransmitter agonists to patients with motor disorders, for the purpose of symptom reduction. In particular the present invention provides methods and compositions for alleviation of akinesia, rigidity and/or tremor associated with Parkinson's disease. | 07-15-2010 |
20100204243 | Process for the Preparation of Poly DL-Lactide-Co-Glycolide Nanoparticles Having Antitubercular Drugs Encapsulated Therein - A process for the preparation of Poly DL-lactide-co-glycolide nanoparticles having antitubercular drugs encapsulated therein comprising: (i) preparation of an aqueous solution of stable water soluble drugs in DW/NS/PBS (ii) preparation of unstable drugs in DW/NS/PBS (iii) preparation of a polymer and hydrophobic drug solution in an organic solvent, (iv) mixing separately the solutions of steps (i) and (ii) with that of step (iii) and sonicating under cold conditions, (v) adding the above emulsion to aqueous PVA and resonicating under cold conditions, (vi) stirring the emulsion 0nd centrifuging the same (vii) washing the said particles, reconstituting the same and lyophilizing. | 08-12-2010 |
20100324067 | TETRACYCLIC DIPYRANO-COUMARIN COMPOUNDS WITH ANTI-HIV AND ANTI-MYCOBACTERIUM TUBERCULOSIS ACTIVITIES - The present invention relates to tetracyclodipyrano-coumarin compounds of general formula (I), wherein the substituents are defined herein. These compounds exihibit dual biological activities of anti human immunodeficiency virus type 1 (HIV-1) infection and anti- | 12-23-2010 |
20110003830 | PROCESS FOR THE PREPARATION OF 3-AMINO-8-(1-PIPERAZINYL)-2H-1-BENZOPYRAN-2-ONE AND SALTS AND SOLVATES THEREOF - The invention relates to a novel process for the preparation of 3-amino-8-(1-piperazinyl)-2H-1-benzopyran-2-one, a broad spectrum 5-HT receptor binding ligand having potent 5-HT | 01-06-2011 |
20110053956 | Treatment for Neurological and Mental Disorders - Methods for treating neurological or mental disorders in humans and the symptoms associated therewith are provided by administering eltoprazine and/or related compounds. In some embodiments, specific symptoms are treated by administering eltoprazine and/or a related compound in an effective amount to ameliorate the symptoms. Of particular significance are symptoms that are associated with cognitive dysfunction where eltoprazine will improve the symptoms and the disorder associated with that symptom. Of particular interest are non-ADHD-associated inattention, hyperactivity and impulsiveness. The methods provided herein are especially useful for improving functional recovery after CNS injury such as stroke where improved cognitive function will facilitate the acquisition of learning and memory of rehabilitative tasks. | 03-03-2011 |
20110065723 | COMPOSITIONS OF N-BENZYL-3-(4-CHLOROPHENYL)-2-[METHYL-[2-OXO-2-(3,4,5-TRIMETHOXYPHENYL)AC- ETYL]AMINO]-N-[3-(4-PYRIDYL)-1-[2-(4-PYRIDYL)ETHYL]PROPYL]PROPANAMIDE AND USES THEREOF - The present invention relates to compositions of N-benzyl-3-(4-chlorophenyl)-2-[methyl-[2-oxo-2-(3,4,5-trimethoxyphenyl)acetyl]amino]-N-[3-(4-pyridyl)-1-[2-(4-pyridyl)ethyl]propyl]propanamide (Timcodar) useful for the treatment of patients with mycobacterium infections such as | 03-17-2011 |
20110086863 | BENZENESULFONANILIDE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5-HT6 RECEPTOR - The present invention relates to novel benzenesulfonanilide compounds of the formulae I and I′ and physiologically tolerated acid addition salts and the N-oxides thereof. The compounds possess valuable therapeutic properties and are particularly suitable, for treating diseases that respond to modulation of the serotonin 5-HT | 04-14-2011 |
20110152289 | DIMERIC DERIVATIVES OF ARTEMISININ AND APPLICATION IN ANTI-CANCER THERAPY - The present invention relates to dimeric derivatives of 10-trifluoromethylated artemisinin of formula (I) below: Formula (I) and the pharmaceutically acceptable salts thereof, and also to the preparation method thereof and to the uses thereof, especially in the treatment of cancer. | 06-23-2011 |
20110183995 | ELTOPRAZINE FOR SUPPRESSION OF L-DOPA INDUCED DYSKINESIAS - This invention relates to the use of the drug Eltoprazine for combating dyskinesias arising from chronic Levodopa (L-DOPA) therapy in patients suffering from Parkinson's disease. | 07-28-2011 |
20110269775 | Piperazine derivatives - Compounds of general formula (I) | 11-03-2011 |
20110281890 | Piperidine and piperazine derivatives - Compounds of general formula (I) | 11-17-2011 |
20110288105 | ELTOPRAZINE FOR THE TREATMENT OF L-DOPA-INDUCED DYSKINESIA - The present invention relates to the treatment of an individual afflicted with L-DOPA-induced dyskinesia, which condition may arise as a consequence of long-term treatment with L-DOPA therapy in Parkinson's patients, the instant treatment comprising administering to the individual an effective amount of eltoprazine or a pharmaceutically acceptable salt thereof. | 11-24-2011 |
20120071495 | Treatment for Neurological and Mental Disorders - Methods for treating neurological or mental disorders in humans and the symptoms associated therewith are provided by administering eltoprazine and/or related compounds. In some embodiments, specific symptoms are treated by administering eltoprazine and/or a related compound in an effective amount to ameliorate the symptoms. Of particular significance are symptoms that are associated with cognitive dysfunction where eltoprazine will improve the symptoms and the disorder associated with that symptom. Of particular interest are non-ADHD-associated inattention, hyperactivity and impulsiveness. The methods provided herein are especially useful for improving functional recovery after CNS injury such as stroke where improved cognitive function will facilitate the acquisition of learning and memory of rehabilitative tasks. | 03-22-2012 |
20120095020 | Cathepsin S Inhibitor Compounds - The present invention provides a compound of Formula (I): | 04-19-2012 |
20120136005 | ELTOPRAZINE FOR THE TREATMENT OF ANXIETY - The present invention relates to the treatment of an individual afflicted with certain forms of anxiety, the instant treatment comprising administering to the individual an effective amount of eltoprazine or a pharmaceutically acceptable salt thereof | 05-31-2012 |
20120149716 | METHODS OF USING AND COMPOSITIONS COMPRISING PDE4 MODULATORS FOR TREATMENT, PREVENTION AND MANAGEMENT OF TUBERCULOSIS - Methods of treating, preventing, and managing tuberculosis and other related disorders are disclosed. The methods comprise the administration of a PDE4 modulator, or a pharmaceutically acceptable salt, solvate, hydrate, clathrate, stereoisomer, or prodrug thereof, optionally in combination with a second active agent and/or other conventional therapies. Pharmaceutical compositions, single unit dosage forms, and kits suitable for use in such methods are also disclosed. | 06-14-2012 |
20120190690 | ELTOPRAZINE FOR THE TREATMENT OF WEIGHT DISORDERS - The present invention relates to the treatment of an individual afflicted with a weight disorder, particularly obesity, the instant treatment comprising administering to the individual an effective amount of eltoprazine or a pharmaceutically acceptable salt thereof. | 07-26-2012 |
20120232094 | USE OF ADRENERGIC N-PHENYLPIPERAZINE ANTAGONISTS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND METHODS OF PREPARING THEM - The present invention describes phenylpiperazinyl alpha adrenergic antagonists that corresponds to the formula (I) | 09-13-2012 |
20120232095 | BENZOFURAN DERIVATIVES - The present invention provides a compound represented by the following formula (I): | 09-13-2012 |
20120232096 | BENZOFURAN DERIVATIVES - The present invention provides a compound represented by the following formula (I): | 09-13-2012 |
20120264764 | Oxabicycloheptanes and Oxabicycloheptenes, Their Preparation and Use - This invention provides compounds having the structure | 10-18-2012 |
20120309768 | NOVEL TUBULIN POLYMERISATION INHIBITORS - The present invention relates to compounds of general formula (I) as tublin polymerisation inhibitors and methods for preparing such compounds. | 12-06-2012 |
20130131081 | PHARMACEUTICAL COMPOSITIONS INCLUDING CARBAMOYLOXY ARYLALKANOYL ARYLPIPERAZINE COMPOUND - A pharmaceutical composition that includes a carbamoyloxy arylalkanoyl arylpiperazine compound SERUM CHOLESTEROL and effectively prevents or treats diabetic nephropathy, diabetic neuropathy, diabetic vascular complications, hyperlipidemia, coronary artery disease, or inflammation. | 05-23-2013 |
20130158048 | Formulation Solution Adapted to Prolong Plasma Times of Drugs in Mammals Including Humans - In the method of administering rifampicin to a human subject, the improvement wherein a prolongation composition is also administered, said prolongation composition comprising: | 06-20-2013 |
20130267538 | TREATMENT OF MITOCHONDRIAL DISEASES - The invention relates the method of treatment or amelioration of mitochondrial disorders such as Alzheimer's disease, Parkinson's disease, Friedreich's ataxia (FRDA), cerebellar ataxias, Leber's hereditary optic neuropathy (LHON), mitochondrial myopathy, encephalopathy, lactacidosis, stroke (MELAS), Myoclonic Epilepsy with Ragged Red Fibers (MERFF), amyotrophic lateral sclerosis (ALS), motor neuron diseases, Huntington's disease, macular degeneration, and epilepsy, with chroman derivatives of Formula I or Formula II as described herein. | 10-10-2013 |
20130303544 | BENZOPYRONE ESTROGEN RECEPTOR REGULATOR - The present invention provides a kind of benzopyrone compounds having a structure of formula (I) and the pharmaceutically acceptable salts or prodrugs thereof, and the pharmaceutical compositions containing such compounds, which can be used to regulate the novel estrogen receptor ER-a36, and prevent and/or treat the related diseases mediated by the ER-a36 receptor, such as cancers, etc. | 11-14-2013 |
20130331399 | Treatment of Motor and Movement Disorder Side Effects Associated with Parkinson's Disease Treatments - This invention provides methods of treating motor disorder side effects associated with the administration of levodopa to a subject having Parkinson's disease, by administering a dose of eltoprazine or a pharmaceutically acceptable acid addition salt thereof. In particular, the invention provides methods for reducing dyskinesia associated with Parkinson's disease treatments, and effective doses of eltoprazine or a pharmaceutically acceptable acid addition salt thereof. | 12-12-2013 |
20140051709 | Compositions and Methods for Treating Myotonic Dystrophy Type 1 - Disclosed is a compound for treatment of Myotonic Dystrophy type 1 having the formula: | 02-20-2014 |
20140142115 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL - This invention relates to compounds having structural Formula I: | 05-22-2014 |
20140155411 | Tuberculosis Biomarkers and Uses Thereof - The present application includes biomarkers, methods, devices, reagents, systems, and kits for the detection, treatment and diagnosis of tuberculosis (TB). In one aspect, the present application includes the identification of biomarkers that can be used alone or in various combinations for the detection of TB, including those set forth in Tables 1, 2, 4, 5, and 8 to 12. In another aspect, the application provides biomarkers that can be used alone or in various combinations to diagnose or prognose TB or follow treatment response. In another aspect, methods are provided for diagnosing TB in an individual, where the methods include detecting, in a biological sample from an individual, at least one biomarker value corresponding to at least one biomarker selected from the group of biomarkers provided in Tables 1, 2, 4, 5, and 8 to 12, wherein the individual is classified as having TB, or the likelihood of the individual having TB is determined, based on the at least one biomarker value. | 06-05-2014 |
20140171444 | Inhibitors of Mycobacterium Tuberculosis Malate Synthase, Methods of Making and Uses Thereof - The present invention provides aryl- or heteroaryl-diketo acid compounds effective to inhibit an activity of a Mycobacterial malate synthase enzyme or to inhibit a malate synthase activity in other bacteria having the enzyme. The compounds may be phenyl- naphthyl-, or thienyl-substituted diketo acids and carboxylate derivatives thereof. Also provided are methods of treating tuberculosis or other pathophysiological conditions associated with a malate synthase enzyme with the inhibitory compounds and methods of in silico design of the inhibitory compounds. In addition, the present invention provides the inhibitory compounds designed by this method. Furthermore, three-dimensional X-ray crystal structures of the Mycobacterial malate synthase complexed with the inhibitory compounds are provided. Further still a method for stabilizing an aromatic or heteroaromatic diketo acid or its prodrug or close analog in solution by derivatizing at least the ortho position on the aromatic ring is provided. | 06-19-2014 |
20140171445 | TREATMENT AND PREVENTION OF DISEASES MEDIATED BY MICROORGANISMS VIA DRUG-MEDIATED MANIPULATION OF THE EICOSANOID BALANCE - The invention provides a method of enhancing the efficacy of antibiotic treatment of tuberculosis, trypanosomiasis, leprosy, and leishmaniasis involving co-administering to a mammal undergoing antibiotic treatment therapeutically effective amounts of a first compound that is an inhibitor of 5-lipoxygenase and optionally a second compound that is a product of the cyclooxygenase pathways. The invention also provides a pharmaceutical composition comprising an antibiotic, an inhibitor of 5-lipoxygenase, and a product of the cyclooxygenase pathways. | 06-19-2014 |
20140243352 | METHODS FOR TREATING DIABETIC COMPLICATIONS WITH CARBAMOYLOXY ARYLALKANOYL ARYLPIPERAZINE COMPOUNDS - A pharmaceutical composition that includes a carbamoyloxy arylalkanoyl arylpiperazine compound and effectively prevents or treats diabetic nephropathy, diabetic neuropathy, diabetic vascular complications, hyperlipidemia, coronary artery disease, or inflammation. | 08-28-2014 |
20140256741 | FLAVONOID COMPOUNDS - The present invention relates to compounds, compositions, and methods for treatment of conditions related to mitochondrial function. In various aspects, the present invention comprises administering one or more epicatechin derivatives in an amount effective to stimulate mitochondrial function in cells. The compounds, compositions, and methods described herein provide for reducing infarct size in the heart following permanent ischemia or ischemia/reperfusion event or method for delaying, attenuating or preventing adverse cardiac remodeling, and can assist in prevention of impaired mitochondria biogenesis and thus prevention of the consequences of impaired mitochondrial biogenesis in various diseases and conditions, as well as provide for the active therapy of mitochondrial depletion that may have already occurred. | 09-11-2014 |
20150045373 | OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES, THEIR PREPARATION AND USE - This invention provides compounds having the structure | 02-12-2015 |
20150087656 | Formulation Solution Adapted to Prolong Plasma Times of Drugs in Mammals Including Humans - Prolongation compositions for prolonging the presence of drugs in blood. | 03-26-2015 |
20150111899 | PIRFENIDONE THERAPY AND INDUCERS OF CYTOCHROME P450 - The present invention relates to methods involving avoiding adverse drug interactions with pirfenidone and CYP inducers, such as smoking. | 04-23-2015 |
20150133469 | EARLY DETECTION OF TUBERCULOSIS TREATMENT RESPONSE - The present invention includes methods for early detection of a treatment response in a patient suspected of being infected with | 05-14-2015 |
20150148353 | OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES FOR THE TREATMENT OF DIABETES - A method of increasing the insulin sensitivity of a mammalian cell by contacting the cell with a protein phosphatase 2A (PP2A) inhibitor having the structure: | 05-28-2015 |
20150299778 | PRIMERS, PROBES, AND METHODS FOR MYCOBACTERIUM TUBERCULOSIS SPECIFIC DIAGNOSIS - Practical and rapid methods for the diagnosis of | 10-22-2015 |
20150368263 | PHARMACEUTICAL FORMULATIONS CONTAINING 3-(4-CINNAMYL-L-PIPERAZINYL) AMINO DERIVATIVES OF 3-FORMYLRIFAMYCIN SV AND 3-FORMYLRIFAMYCIN S AND A PROCESS OF THEIR PREPARATION - The present invention related to a process of preparation of pharmaceutically acceptable formulations containing as active substance 3-(4-cinnamyl-1-piperazinyl)-amino derivatives of 3-formylrifamycine SV and 3-formylrifamycine S, which possess high activity against Gram-positive and Gram-negative microorganisms, as well as against tuberculous micobacteria (including atypical and rifamycin resistant), and to a method for the preparation of 3-(4-cinnamyl-1-piperazinyl)-amino derivatives of 3-formylrifamycine SV and 3-formylrifamycine S. The method for the preparation of pharmaceutical compositions is readily feasible, and does not require special equipment for its implementation. The process for preparing the compounds is characterized by high yield and purity, using an environmental clean solvent-ethanol and water in the preparation and isolation of substances, and the absence of residual organic solvents in the final product. | 12-24-2015 |
20160051544 | FORMULATIONS OF OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES - The invention relates to a pharmaceutical composition comprising a protein phosphatase 2A (PP2A) inhibitor and monosodium glutamate. | 02-25-2016 |
20160067244 | Treatment for Neurological and Mental Disorders - Methods for treating neurological or mental disorders in humans and the symptoms associated therewith are provided by administering eltoprazine and/or related compounds. In some embodiments, specific symptoms are treated by administering eltoprazine and/or a related compound in an effective amount to ameliorate the symptoms. Of particular significance are symptoms that are associated with cognitive dysfunction where eltoprazine will improve the symptoms and the disorder associated with that symptom. Of particular interest are non-ADHD-associated inattention, hyperactivity and impulsiveness. The methods provided herein are especially useful for improving functional recovery after CNS injury such as stroke where improved cognitive function will facilitate the acquisition of learning and memory of rehabilitative tasks. | 03-10-2016 |
20160082006 | PHARMACOLOGICAL TREATMENT OF PARKINSON'S DISEASE - The present invention relates to the co-administration of two neurotransmitter agonists to patients with motor disorders, for the purpose of symptom reduction. In particular the present invention provides methods and compositions for alleviation of akinesia, rigidity and/or tremor associated with Parkinson's disease. | 03-24-2016 |
20160199370 | ACTIVATORS OF HUMAN PYRUVATE KINASE | 07-14-2016 |
20160251330 | CHROMENE DERIVATIVES AS INHIBITORS OF TCR-NCK INTERACTION | 09-01-2016 |